2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial

Inflammatory Bowel Diseases

Volumn 23, Issue 5, 2017, Pages 822-832

  Suzuki, Yasuo ^a   Iida, Mitsuo ^b   Ito, Hiroaki ^c   Nishino, Haruo ^d   Ohmori, Toshihide ^e   Arai, Takehiro ^f   Yokoyama, Tadashi ^g,h   Okubo, Takanori ⁱ   Hibi, Toshifumi ^j  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b Department of Medicine   (Japan)

^c Kinshukai Infusion Clinic   (Japan)

^d Matsushima Clinic   (Japan)

^e Ohmori Toshihide Gastro Intestinal Clinic   (Japan)

^f Toukatsu Tsujinaka Hospital   (Japan)

^g Yokoyama Hospital for Gastroenterological Diseases   (Japan)

^h Yokoyama IBD Clinic   (Japan)

ⁱ ZERIA PHARMACEUTICAL CO LTD   (Japan)

^j KITASATO UNIVERSITY   (Japan)

more..

Author keywords

3 times daily administration; Asacol; maintenance of remission; mesalamine; once daily administration; ulcerative colitis

Indexed keywords

EUDRAGIT; MESALAZINE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL DISTENSION; ADULT; ALLERGIC PNEUMONITIS; ANUS FISTULA; ARTICLE; CONTROLLED STUDY; DENTAL CARIES; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE COURSE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; EVENING DOSAGE; FEMALE; HERPES ZOSTER OTICUS; HUMAN; INGUINAL HERNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RECURRENCE RISK; RETINA DETACHMENT; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; TIBIA FRACTURE; ULCERATIVE COLITIS; ULCERATIVE COLITIS DISEASE ACTIVITY INDEX; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DRUG ADMINISTRATION; EQUIVALENCE TRIAL (TOPIC); FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PROGNOSIS; REMISSION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EQUIVALENCE TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; PROGNOSIS; REMISSION INDUCTION; YOUNG ADULT;

EID: 85019834226     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001065     Document Type: Article

References (13)

1. Research Group for Intractable Inflammatory Bowel Disease. Guidelines for the management of ulcerative colitis in Japan-developed through integration of evidence and consensus among experts. January, 2006. Available at: http:// minds4. jcqhc. or. jp/minds/kaiyouseida/ucgl+201102. pdf. Accessed August 18, 2016.
2. Kane SV. Systematic review: Adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
3. Higgins PDR, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247-257.
4. Ford AC, Khan KJ, Sandborn WJ, et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:2070-2077.
5. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayedrelease oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010;138:1286-1296.
6. Watanabe M, Hanai H, Nishino H, et al. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: A double-blind, double-dummy, randomized multicenter study. Inflamm Bowel Dis. 2013;19:1681-1690.
7. Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study. Inflamm Bowel Dis. 2010;16:1575-1582.
8. Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission Aliment Pharmacol Ther. 1999;13:373-379.
9. Hawkey CJ, Dube LM, Rountree LV, et al. A trial of zileuton versus mesalazine or placebo in the maintenance of remission ulcerative colitis. Gastroenterology. 1997;112:718-724.
10. Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: A 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther. 2009;30: 908-918.
11. Ng SC, Tsoi KKF, Kamm MA, et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:1164-1176.
12. Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:CD000544.
13. Acosta MB, Vallejo N, Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (mayo score 0 vs 1): A longitudinal cohort study. J Crohns Colitis. 2016;10:13-19.